LUCD - NASDAQ
Lucid Diagnostics Inc.
$1.00
-0.99%Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
At a Glance
Live SnapshotLucid Diagnostics Inc. Management Team
Dr. Lishan Aklog M.D.
Chairman & Chief Executive Officer
Compensation
$300,000
Mr. Dennis M. McGrath CPA
Chief Financial Officer
Compensation
$225,000
Dr. Suman M. Verma M.D., Ph.D.
Chief Scientific Officer
Dr. Brian J. deGuzman M.D.
Chief Technology & Compliance Officer
Dr. Amitabh Chak M.D.
Co-Founder & Strategic Advisor
Dr. Sanford D. Markowitz M.D., Ph.D.
Co-Founder & Strategic Advisor
Compensation
$14,535
Helen Moinova Ph.D.
Co-Founder & Strategic Advisor
Dr. Joseph Willis M.D.
Co-founder & Strategic Advisor
Mr. Michael Adam Gordon
General Counsel & Secretary
Compensation
$250,000
Mr. Shaun M. O'Neill M.B.A.
President & Chief Operating Officer
Compensation
$300,000
Lucid Diagnostics Inc. Insider Positioning
During the last 12 months, insiders have purchased $569K worth of LUCD shares, with no selling activity reported.
3 Months
245.0K
245.27K
0
0.00
+245K
+$245K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
215.0K
221.45K
0
0.00
+221K
+$221K
9-12 Months
100.0K
101.84K
0
0.00
+102K
+$102K
Top Buyers
Matheis Dennis
Director
$347K
Palumbo John R
Director
$221K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $569K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
LUCD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | April 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 06, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | April 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | May 01, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | May 02, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.